This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

NICE - gastroparesis in type 1 diabetes

Authoring team

  • a small-particle-size diet (mashed or pureed food) is advised for symptomatic relief for adults with type 1 diabetes who have vomiting caused by gastroparesis
  • continuous subcutaneous insulin infusion (CSII or insulin pump) therapy should be considered for adults with type 1 diabetes who have gastroparesis

For adults with type 1 diabetes who have vomiting caused by gastroparesis, explain that:

  • there is no strong evidence that any available antiemetic therapy is effective
  • some people have had benefit with domperidone, erythromycin or metoclopramide
  • the strongest evidence for effectiveness is for domperidone, but prescribers must take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines

For treating vomiting caused by gastroparesis in adults with type 1 diabetes:

  • alternating use of erythromycin and metoclopramide should be considered
  • use domperidone only in exceptional circumstances (that is, when it is the only effective treatment) and in accordance with MHRA guidance

Refer adults with type 1 diabetes who have gastroparesis for specialist advice if the interventions above are not beneficial or not appropriate

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.